Lexicon Pharmaceuticals (LXRX) EBT Margin (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) reported EBT Margin of 4.72% for Q1 2026, up 203007.0% year-over-year from N/an in Q1 2025, and up 98.25% on a QoQ basis from 269.07% in Q4 2025.
Lexicon Pharmaceuticals (LXRX) has 16 years of EBT Margin data on file, last reported at 4.72% in Q1 2026.
- Quarterly EBT Margin rose 203007.0% year-over-year to 4.72% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 34.79% (up 53377.0% YoY) and the FY2025 annual result came in at 98.21%, up 53600.0% from the prior year.
- EBT Margin improved to 4.72% in Q1 2026 per LXRX's latest filing, from 269.07% in the prior quarter.
- Across five years, EBT Margin topped out at 12.94% in Q2 2025 and bottomed at 33043.21% in Q3 2023.
- The 4-year median for EBT Margin is 2697.84% (2024), against an average of 5614.31%.
- The widest annual swing landed in 2024, when EBT Margin jumped 2940361 bps; it then slumped 14579 bps in 2025.
- Tracing LXRX's EBT Margin over 4 years: stood at 6101.44% in 2023, then jumped by 98 bps to 123.28% in 2024, then tumbled by 118 bps to 269.07% in 2025, then soared by 98 bps to 4.72% in 2026.
- Per Business Quant, the three latest LXRX EBT Margin figures stand at 4.72% (Q1 2026), 269.07% (Q4 2025), and 85.93% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.40% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 41.95% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 23.05% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 18.99% |
| 10 | Lexicon Pharmaceuticals | 872.52 Mn | 701.87 Mn | 20.99 Mn | -4.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.72% |
| Dec 31, 2025 | -269.07% |
| Sep 30, 2025 | -85.93% |
| Jun 30, 2025 | 12.94% |
| Mar 31, 2025 | -2,034.79% |
| Dec 31, 2024 | -123.28% |
| Sep 30, 2024 | -3,639.60% |
| Jun 30, 2024 | -3,360.90% |
| Mar 31, 2024 | -4,147.58% |
| Dec 31, 2023 | -6,101.44% |
| Sep 30, 2023 | -33,043.21% |
| Jun 30, 2023 | -14,574.13% |
| Dec 31, 2021 | 9,022.89% |
| Jun 30, 2021 | -7,747.01% |
| Mar 31, 2021 | -77,800.00% |
| Dec 31, 2020 | 23.12% |
| Jun 30, 2020 | -278,816.00% |
| Mar 31, 2020 | -844.72% |
| Dec 31, 2019 | -585.97% |
| Sep 30, 2019 | 74.74% |
| Jun 30, 2019 | -244.88% |
| Mar 31, 2019 | -926.04% |
| Dec 31, 2018 | -98.31% |
| Sep 30, 2018 | -393.28% |
| Jun 30, 2018 | -251.53% |
| Mar 31, 2018 | -165.82% |
| Dec 31, 2017 | -77.52% |
| Sep 30, 2017 | -111.01% |
| Jun 30, 2017 | -290.06% |
| Mar 31, 2017 | -242.42% |
| Dec 31, 2016 | -97.39% |
| Jun 30, 2016 | -189.72% |
| Mar 31, 2016 | -279.20% |
| Dec 31, 2015 | 68.10% |
| Sep 30, 2015 | -6,248.06% |
| Jun 30, 2015 | -7,538.03% |
| Mar 31, 2015 | -1,575.28% |
| Dec 31, 2014 | -20.20% |
| Sep 30, 2014 | -9,732.70% |
| Jun 30, 2014 | -3,929.29% |
| Mar 31, 2014 | -11,162.82% |
| Dec 31, 2013 | -1,236.31% |
| Sep 30, 2013 | -13,306.30% |
| Jun 30, 2013 | -13,586.92% |
| Mar 31, 2013 | -7,224.44% |
| Dec 31, 2012 | -11,448.17% |
| Sep 30, 2012 | -7,941.67% |
| Jun 30, 2012 | -13,041.21% |
| Mar 31, 2012 | -9,954.67% |
| Dec 31, 2011 | -9,867.35% |
| Sep 30, 2011 | -7,352.96% |
| Jun 30, 2011 | -4,805.05% |
| Mar 31, 2011 | -4,975.84% |
| Dec 31, 2010 | -1,835.51% |
| Sep 30, 2010 | -3,526.12% |
| Jun 30, 2010 | -1,995.38% |